We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is BioTelemetry (BEAT) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. BioTelemetry (BEAT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of BEAT and the rest of the Medical group's stocks.
BioTelemetry is one of 841 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. BEAT is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for BEAT's full-year earnings has moved 8.70% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, BEAT has returned 8.72% so far this year. At the same time, Medical stocks have gained an average of 1.77%. This means that BioTelemetry is outperforming the sector as a whole this year.
Looking more specifically, BEAT belongs to the Medical Services industry, a group that includes 31 individual stocks and currently sits at #110 in the Zacks Industry Rank. On average, this group has gained an average of 5.48% so far this year, meaning that BEAT is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track BEAT. The stock will be looking to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is BioTelemetry (BEAT) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. BioTelemetry (BEAT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of BEAT and the rest of the Medical group's stocks.
BioTelemetry is one of 841 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. BEAT is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for BEAT's full-year earnings has moved 8.70% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, BEAT has returned 8.72% so far this year. At the same time, Medical stocks have gained an average of 1.77%. This means that BioTelemetry is outperforming the sector as a whole this year.
Looking more specifically, BEAT belongs to the Medical Services industry, a group that includes 31 individual stocks and currently sits at #110 in the Zacks Industry Rank. On average, this group has gained an average of 5.48% so far this year, meaning that BEAT is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track BEAT. The stock will be looking to continue its solid performance.